Pharvaris director Glassman discloses option holdings
Pharvaris N.V. director Robert Glassman filed an initial ownership report showing his existing equity position.
Rhea-AI Filing Summary
Pharvaris N.V. director Robert Glassman filed an initial ownership report showing his existing equity position. He reports several stock option awards on common stock, including options over 16,500 shares at an exercise price of $28.00, 15,000 shares at $16.05, 14,000 shares at $22.31, 21,000 shares at $8.05, 14,493 shares at $18.14, and 8,000 shares at $20.00, with expirations between 2031 and 2036. He also holds 23,300 option-underlying shares at $7.89 and 15,167 shares of common stock directly, plus 5,500 restricted stock units that will fully vest on March 3, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Glassman Robert
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 112,293 contracts (Direct);
Common Stock — 15,167 shares (Direct)
Footnotes (6)
- F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.
- F2. 100% of the option vest on the 12-month anniversary.
- F3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F5. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F6. 25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Pharvaris (PHVS) Form 3 filing by Robert Glassman show?
The Form 3 shows director Robert Glassman’s existing equity holdings in Pharvaris. It lists multiple stock option grants, directly held common shares, and restricted stock units with specified exercise prices, expiration dates, and vesting terms as of the reporting date.
How many Pharvaris stock options does Robert Glassman report on Form 3?
Robert Glassman reports several stock option awards on Pharvaris common stock. These include option positions over 16,500, 15,000, 14,000, 21,000, 14,493, 8,000, and 23,300 underlying shares, each with its own exercise price and expiration date disclosed in the filing.
What common stock holdings does Robert Glassman report in Pharvaris (PHVS)?
He reports holding 15,167 shares of Pharvaris common stock directly. These are listed separately from his option positions and restricted stock units, giving investors a view of his current direct share ownership at the time of the Form 3 filing.
What restricted stock units does Robert Glassman hold in Pharvaris?
The filing notes 5,500 restricted stock units from an award granted March 3, 2026. These units will vest 100% on March 3, 2027 and settle in Pharvaris common stock, and are reported as non-derivative securities in the ownership tables.
Are there any buy or sell transactions in the Pharvaris Form 3 for Robert Glassman?
The Form 3 records Glassman’s existing holdings rather than new trades. The summarized data show only holding entries, with no classified open-market purchases, sales, exercises, gifts, or other transactional activity during the reported period.
What are the expiration dates of Robert Glassman’s Pharvaris stock options?
Glassman’s Pharvaris stock options have expiration dates ranging from 2031 to 2036. Individual grants expire on dates including February 5, 2031, January 1, 2031, April 1, 2032, April 6, 2033, April 11, 2034, March 12, 2035, and March 3, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
